Breaking News

Longboard Prescription drugs to Current at Two Approaching Investor Conferences | Information

SAN DIEGO, Aug. 31, 2021 (World NEWSWIRE) — Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a medical-stage biopharmaceutical corporation targeted on creating novel, transformative medicines for neurological illnesses, nowadays introduced that Kevin R. Lind, Longboard’s President & Chief Govt Officer, will existing almost in a fireside chat format at two approaching investor conferences: Citi’s 16th Once-a-year BioPharma Virtual Meeting and H.C. Wainwright’s 23rd Yearly Worldwide Investment decision Convention.

Citi’s BioPharma Conference: Wednesday, September 8, 2021, at 3:15 PM ETH.C. Wainwright’s World wide Investment decision Conference: Webcast offered beginning Monday, September 13, 2021, at 7:00 AM ET

To accessibility stay webcasts of Longboard’s shows, make sure you take a look at the “ Gatherings & Displays ” web page in just the Investors Relations part of Longboard’s web page at https://ir.longboardpharma.com/. Replays of the webcasts will be out there shortly after the completion of the activities and archived on the site for at minimum 30 times.

About Longboard Prescribed drugs Longboard Pharmaceuticals, Inc. is a scientific-stage biopharmaceutical organization centered on developing novel, transformative medications for neurological illnesses. Longboard was fashioned in January 2020 by Arena Prescribed drugs, Inc. (Arena) to progress a portfolio of centrally performing item candidates made to be hugely selective for distinct G protein-coupled receptors (GPCRs). Longboard’s small molecule merchandise candidates were being discovered out of the exact same system at Arena that signifies a end result of extra than 20 years of GPCR investigation. Longboard is evaluating LP352, an oral, centrally performing, 5-hydroxytryptamine 2c receptor subtype superagonist, with negligible noticed impact on 5-HT2b and 5-HT2a receptor subtypes, in growth for the prospective treatment of developmental and epileptic encephalopathies. Longboard is also analyzing LP143, a centrally performing, full cannabinoid style 2 receptor agonist, in development for the possible treatment of neurodegenerative ailments associated with neuroinflammation caused by microglial activation, and LP659, a centrally performing, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in improvement for the probable therapy of central anxious procedure neuroinflammatory diseases.

Forward-Wanting Statements Sure statements in this press release are ahead-hunting statements that include a variety of challenges and uncertainties. These types of ahead-seeking statements include things like statements about Longboard’s participation in the upcoming conferences, scientific and preclinical packages, ability to establish medicines, and concentrate. For these kinds of statements, Longboard statements the protection of the Personal Securities Litigation Reform Act of 1995. True gatherings or effects may perhaps differ materially from Longboard’s anticipations. Factors that could induce true effects to vary materially from these stated or implied by Longboard’s forward-seeking statements are disclosed in Longboard’s filings with the Securities and Exchange Fee (SEC). These ahead-searching statements symbolize Longboard’s judgment as of the time of this release. Longboard disclaims any intent or obligation to update these ahead-hunting statements, other than as may perhaps be needed under applicable regulation.

Company Call: Megan E. Knight Head of Investor Relations mknight@longboardpharma.com IR@longboardpharma.com 619.592.9775

Copyright 2021 GlobeNewswire, Inc.